- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
NGL Fine-Chem delivered strong Q4 & FY26 results, indicating a significant recovery. Q4 revenue hit ₹149.23 Cr (+57% YoY), with FY26 revenue reaching ₹500.95 Cr (+36% YoY). PAT more than doubled for the year to ₹48.13 Cr. Management reports broad-based demand and securing partial price increases for Q1 FY27. They target 15-18% EBITDA margins from Q2 FY27. Capacity expansion: Phase I is operational, Phase II commissioning by early Q2 FY27. USFDA filings are underway, with Europe sales expected this year and US sales in FY28. Outlook is positive for continued growth, but strong competition persists.